PAUL HOPKINS to Heterozygote
This is a "connection" page, showing publications PAUL HOPKINS has written about Heterozygote.
Connection Strength
0.274
-
Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction. Arterioscler Thromb. 1991 Sep-Oct; 11(5):1137-46.
Score: 0.076
-
Defining the challenges of familial hypercholesterolemia screening: introduction. J Clin Lipidol. 2010 Sep-Oct; 4(5):342-5.
Score: 0.071
-
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. J Clin Lipidol. 2018 Mar - Apr; 12(2):390-396.e8.
Score: 0.029
-
The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred. J Clin Lipidol. 2018 Jan - Feb; 12(1):152-161.
Score: 0.029
-
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017 Nov - Dec; 11(6):1338-1346.e7.
Score: 0.029
-
Lack of association of glutamate decarboxylase 2 gene polymorphisms with severe obesity in utah. Obesity (Silver Spring). 2006 Apr; 14(4):650-5.
Score: 0.013
-
Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005 Sep; 116(3):682-8.
Score: 0.013
-
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet. 2004 Mar; 114(4):349-53.
Score: 0.011
-
Clinical application of deoxyribonucleic acid markers in a Utah family with hypercholesterolemia. Am J Cardiol. 1989 Jan 01; 63(1):109-12.
Score: 0.004